arrow
T

T. Yoshino

National Cancer Center Hospital East
H指数:26
被引数:2,797

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)

一项关于厄洛替尼用于BRAF V600E突变型转移性结直肠癌的多中心II期研究:BRAVERY研究(EPOC1701)

2025-10-090
OAAI
Encorafenib plus cetuximab (EC) plus FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

Encorafenib plus cetuximab (EC) plus FOLFIRI用于BRAF V600E突变型转移性结直肠癌(mCRC):BREAKWATER安全性导入期(SLI)的最新结果

2024-09-011
PRE
Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2

根据基线时的预后因素,fruquintinib对经过大量预处理的转移性结直肠癌患者的影响: FRESCO-2的探索性分析

2024-06-010
PRE
Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
2021-07-019
OAAI
Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
2015-09-010
PREAI
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
2014-11-014
PREAI
Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology
LEUKEMIA
IF13.4
2012-11-2730
PREAI